LONDON, May 31, 2017 /PRNewswire/ --
New findings highlight complexity of receptor interactions and provide crucial insights for development of peptide and small molecule therapeutics - research published in Nature
Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of
The findings, published in Nature, provide insight to the molecular mechanism of action of GLP-1 peptides and their interactions with the receptor. Importantly, this pioneering research further validates and enables the application of structure-based methods to the design of optimised peptide therapeutics and small molecules targeting the GLP-1 receptor, and related G protein-coupled receptors (GPCRs), for treating a range of diseases. The research was published online in Nature today and can be accessed at http://dx.doi.org/10.1038/nature22800.
GLP-1 is an important peptide hormone that regulates glucose homeostasis through control of insulin release from the pancreas. Activating the GLP-1 receptor is one of the most important and highly validated mechanisms for treating Type 2 diabetes, and awareness is increasing about the potential of this target in treating other metabolic diseases, as well as cardiovascular and neurological diseases. A number of GLP-1 peptide agonists, with improved stability and duration of action compared to native GLP-1, are already approved for treating Type 2 diabetes, including exenatide (Byetta®/Bydureon®), liraglutide (Victoza®, Saxenda®), lixisenatide (Lyxumia®), albiglutide (Tanzeum®) and dulaglutide (Trulicity®).
Fiona Marshall, Chief Scientific Officer of Heptares and Sosei, said: "The findings from this research at Heptares are ground-breaking and very exciting: they unveil a remarkably complex network of interactions between GLP-1 peptide ligands and the receptor that explain why it has been so difficult to mimic this effect with a small molecule. Understanding these interactions at a molecular level may be the breakthrough that enables the design of small molecule drugs, as well as optimised therapeutic peptides, targeting not only the GLP-1 receptor but also other closely related GPCR targets implicated in many diseases."
The GLP-1 receptor is a member of the Class B secretin group of GPCRs, a family of structurally similar receptors for peptide hormones such as GLP-1, glucagon, corticotropin-releasing factor (CRF), calcitonin and parathyroid peptide hormone. Class B GPCRs include many therapeutic targets for cardiovascular diseases, metabolic diseases, bone diseases and migraine, but despite strong clinical validation, structural information is limited.
About Heptares Therapeutics
Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, MedImmune, MorphoSys, Pfizer and Teva.
Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.sosei.com.
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR® is a registered trademark in the EU and Japan.
Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For more information about Sosei, please visit www.sosei.com .
Reference Jazayeri, A et al. Crystal structure of the GLP-1 receptor bound to a peptide agonist (2017) Nature http://dx.doi.org/10.1038/nature22800 Bydureon® and Byetta® are registered trademarks of the AstraZeneca group of companies. Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Lixumia® is a registered trademark of Sanofi. Tanzeum® is a registered trademark of the GSK group of companies. Trulicity® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
SOURCE Heptares Therapeutics
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All